MeSH tree: C20.683.460
The U.S. Food and Drug Administration has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) as a single-agent treatment for adult patients with high-risk smoldering multiple myeloma (HR-SMM).
Nov 13, 2025
0
23
A new risk assessment score developed by researchers at Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, and Massachusetts General Hospital reveals how multiple myeloma, a form of blood cancer, begins ...
May 21, 2025
0
25
A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk SMM carries a higher likelihood ...
Dec 10, 2024
0
0
In a systematically screened population, there is no association between autoimmune disease and monoclonal gammopathy of undetermined significance (MGUS), according to a study published online May 21 in the Annals of Internal ...
May 21, 2024
0
0
A new review paper was published in Oncotarget, titled "Systemic AL amyloidosis: current approach and future direction."
May 5, 2023
0
26
